Assessment of immunogenicity of romiplostim in clinical studies with ITP subjects

Jawa, Vibha; Hokom, Martha; Zheng Hu; El-Abaadi, Naglaa; Yao Zhuang; Berger, Dietmar; Gupta, Shalini; Swanson, Steven J.; Chirmule, Narendra; Hu, Zheng; Zhuang, Yao
July 2010
Annals of Hematology;Jul2010, Vol. 89, p75
Academic Journal
journal article
Romiplostim is an Fc-peptide fusion protein that activates intracellular transcriptional pathways via the thrombopoietin (TPO) receptor leading to increased platelet production. Romiplostim has been engineered to have no amino acid sequence homology to endogenous TPO. Recombinant protein therapeutics can be at a risk of development of an antibody response that can impact efficacy and safety. Hence, a strategy to detect potential antibody formation to the drug and to related endogenous molecules can be useful. The immunogenicity assessment strategy involved both the detection and characterization of binding and neutralizing antibodies. The method for detection was based on a surface plasmon resonance biosensor platform using the Biacore 3000. Samples that tested positive for binding antibodies in the Biacore immunoassay were then tested in a neutralization assay. Serum samples from 225 subjects with immune thrombocytopenic purpura (ITP) dosed with romiplostim and 45 ITP subjects dosed with placebo were tested for romiplostim and TPO antibodies. Prior to romiplostim treatment, 17 subjects (7%) tested romiplostim antibody positive and 12 subjects (5%) tested TPO antibody positive for pre-existing binding antibodies. After romiplostim exposure, 11% of the subjects exhibited binding antibodies against romiplostim and 5% of the subjects with ITP showed binding antibodies against TPO. The antibodies against romiplostim did not cross-react with TPO and vice versa. No cases of anti-TPO neutralizing antibodies were detected in romiplostim-treated subjects. The incidence of anti-romiplostim neutralizing antibodies to romiplostim was 0.4% (one subject); this subject tested negative at the time of follow-up 4 months later. No impact on platelet profiles were apparent in subjects that had antibodies to romiplostim to date. In summary, administration of romiplostim in ITP subjects resulted in the development of a binding antibody response against romiplostim and TPO ligand. One subject developed a neutralizing antibody response to romiplostim that impacted the platelet counts of this subject. No neutralizing antibodies to endogenous TPO were observed.


Related Articles

  • Epidemiology, pathophysiology, and initial management of chronic immune thrombocytopenic purpura. Pruemer, Jane // American Journal of Health-System Pharmacy;1/16/2009, Vol. 66 Issue S2, pS4 

    Purpose. The incidence and epidemiology, the pathogenesis, the clinical symptoms and diagnosis and the first-line therapies for the management of chronic immune thrombocytopenic purpura (ITP) are discussed. In addition, the recommendations of two expert panels for the management of ITP are...

  • Evaluation of 143 Cases of Immune Thrombocytopenic Purpura With Regards to Clinical Course and Response to Treatment. Albayrak, Murat; Balcik, Ozlem Sahin; Zeynep Aki, Sahika; Gokmen, Ayla; Ceran, Funda; Yokus, Osman; Dagdas, Simten; Ayli, Meltem; Ozet, Gulsum // Eurasian Journal of Medicine;Dec2010, Vol. 42 Issue 3, p120 

    Objective: Immune thrombocytopenic purpura (ITP) is also known as idiopathic thrombocytopenic purpura. Increased platelet destruction and insufficient platelet production are both responsible for its etiopathogenesis. ITP can be diagnosed after excluding other possible causes of...

  • Immune-mediated thrombocytopenic purpura associated with Toxoplasma gondii infection in an immunocompetent patient. Deutsch, Melanie; Nezi, Vasiliki; Kountouras, Dimitris; Belegrati, Maria; Kalmantis, Themistocles; Dourakis, Spiros P // Hematology Journal;2004, Vol. 5 Issue 6, p538 

    Infection with Toxoplasma gondii (T. gondii) in immunocompetent adults is usually asymptomatic and needs no specific therapy. We report the case of a 16-year-old previous healthy adolescent who presented with bleeding due to immune-mediated thrombocytopenic purpura during an acute acquired T....

  • Management of Immune Thrombocytopenic Purpura in Adults. Stasi, Roberto; Provan, Drew // Mayo Clinic Proceedings;Apr2004, Vol. 79 Issue 4, p504 

    Primary immune thrombocytopenic purpura (ITP), also referred to as idiopathic thrombocytopenic purpura, is an organ-specific autoimmune disorder in which antibodycoated or immune complex-coated platelets are destroyed prematurely by the reticuloendothelial system, resulting in peripheral blood...

  • Eltrombopag Tablets (Promacta). Elliot, William T.; Chan, James // Internal Medicine Alert;3/15/2009, Vol. 31 Issue 5, p37 

    The article presents a drug study of Eltrombopag Tablets (Promacta), a thrombopoietin (TPO) receptor agonist. The drug is intended for thrombocytopenia in patients associated with chronic immune (idiopathic) thrombocytopenia purpura. Moreover, it also provides the drug's dosage, potential...

  • Treatment Options for Chronic Immune Thrombocytopenic Purpura.  // American Journal of Health-System Pharmacy;1/16/2009, Vol. 66 Issue S2, pS22 

    A quiz concerning the treatment options for chronic immune thrombocytopenic purpura is presented.

  • Cerebral Venous Thrombosis After Immune Thrombocytopenic Purpura and Anti-D Immune Globulin Therapy. Kayyali, Husam R.; Abdelmoity, Ahmed T.; Morriss, M. Craig; Graf, William D. // Journal of Child Neurology;Mar2008, Vol. 23 Issue 3, p325 

    Cerebral venous thrombosis has multiple etiologies and a wide variety of clinical manifestations This article reports on a young girl who developed cerebral venous thrombosis after intravenous anti-D immune globulin therapy for immune thrombocytopenic purpura. In this case, venous infarction was...

  • Neonatal Isoimmune Thrombocytopenia. Katz, Jacob; Hodder, Felicity S.; Aster, Richard S.; Bennetts, Geni A.; Cairo, Mitchell S. // Clinical Pediatrics;Mar1984, Vol. 23 Issue 3, p159 

    Isoimmune neonatal thrombocytopenia purpura (INTP) is a disease caused by platelet destruction by maternally derived antibody. Six patients were investigated. Maternal derived platelet transfusions in two patients resulted in posttransfusion platelet counts of greater than 85.000/μl. a normal...

  • Immune Thrombocytopenic Purpura. Cines, Douglas B.; Blanchette, Victor S. // New England Journal of Medicine;3/28/2002, Vol. 346 Issue 13, p995 

    Presents a review that focuses on the diagnosis and management of primary immune thrombocytopenic purpura, an auto immune disorder characterized by a low platelet count and mucocutaneous bleeding. Description of the disorder and its occurrence in children and adults; Possible causes of the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics